Señales en vivo de VIRI | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 may 2024 @ 16:00):

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response...

Stats
Volumen de hoy	605 306
Volumen promedio	587 184
Capitalización de mercado	5.97M
EPS	$0 ( 2024-05-09 )
Próxima fecha de ganancias	( $-0.0700 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.800
ATR14	$0.00200 (0.92%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-26	Pridgen William	Buy	2 917	Stock Option (right to buy)
2024-02-26	Thomas John C	Buy	4 167	Stock Option (right to buy)
2024-02-26	Whitley Richard James	Buy	4 000	Stock Option (right to buy)
2024-02-26	Keefer David R	Buy	4 709	Stock Option (right to buy)
2024-02-26	Burch Richard Alan	Buy	2 917	Stock Option (right to buy)

INSIDER POWER
99.86
Last 92 transactions
Buy: 2 833 595 \| Sell: 299 106

Volumen Correlación

Largo: 0.10 (neutral)

Corto: 0.16 (neutral)

Signal:(56.839) Neutral

Virios Therapeutics, LLC Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Virios Therapeutics, LLC Correlación - Moneda/Commodity

0.46
( neutral )

0.31
( neutral )

0.00
( neutral )

-0.29
( neutral )

Virios Therapeutics, LLC Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.280

FY	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-0.280

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-1.100

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-3.24

Financial Reports:

No articles found.

Virios Therapeutics, LLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Virios Therapeutics, LLC

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.